ROQ Stock Overview
A material biotech company, engages in the development of medicines for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Roquefort Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.043 |
| 52 Week High | UK£0.095 |
| 52 Week Low | UK£0.033 |
| Beta | -0.29 |
| 1 Month Change | 11.69% |
| 3 Month Change | 28.36% |
| 1 Year Change | -38.57% |
| 3 Year Change | -59.05% |
| 5 Year Change | n/a |
| Change since IPO | -36.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| ROQ | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 7.5% | -4.6% | -1.4% |
| 1Y | -38.6% | -22.2% | 4.6% |
Return vs Industry: ROQ underperformed the UK Biotechs industry which returned -17.4% over the past year.
Return vs Market: ROQ underperformed the UK Market which returned 17.5% over the past year.
Price Volatility
| ROQ volatility | |
|---|---|
| ROQ Average Weekly Movement | 14.7% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: ROQ's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: ROQ's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 10 | Ajan Reginald | www.roquefortplc.com |
Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy, toxicology studies, and orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics for solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo efficacy; and MK cell therapy with direct and natural killer cell-mediated anti-cancer action. The company was incorporated in 2020 and is based in London, the United Kingdom.
Roquefort Therapeutics plc Fundamentals Summary
| ROQ fundamental statistics | |
|---|---|
| Market cap | UK£5.55m |
| Earnings (TTM) | -UK£1.54m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.6x
P/E RatioIs ROQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ROQ income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£16.00k |
| Gross Profit | -UK£16.00k |
| Other Expenses | UK£1.53m |
| Earnings | -UK£1.54m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.012 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 12.4% |
How did ROQ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/17 11:52 |
| End of Day Share Price | 2024/12/17 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Roquefort Therapeutics plc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|